Parkman R
Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital of Los Angeles, California 90054.
Annu Rev Med. 1991;42:189-97. doi: 10.1146/annurev.me.42.020191.001201.
Graft-versus-host disease, both acute and chronic, continues to be the major complication of human bone marrow transplantation. Improved posttransplant chemoprophylaxis has reduced the incidence of acute graft-versus-host disease, but the incidence of the chronic form of the disease remains unchanged. The use of donors that are not genotypically identical at the major histocompatibility complex increases the incidence of acute and chronic graft-versus-host disease. The clinical consequences of acute and chronic graft-versus-host disease are discussed.
移植物抗宿主病，包括急性和慢性，仍然是人类骨髓移植的主要并发症。改进的移植后化学预防措施降低了急性移植物抗宿主病的发生率，但慢性移植物抗宿主病的发生率仍未改变。使用在主要组织相容性复合体上基因不匹配的供体，会增加急慢性移植物抗宿主病的发生率。本文讨论了急慢性移植物抗宿主病的临床后果。
